How I Decide When to Prescribe GLP-1 Agonists (and When I Don’t)

 

Lately, I get this question more often than I did a year ago. 

“Should I be on a GLP-1 drug?” 

I hear it from both patients and other doctors, and it almost always comes with one expectation: weight loss. 

That’s usually where the conversation begins, but it’s not where my decision-making starts. 

I don’t see GLP-1 receptor agonists mainly as weight loss drugs. To me, they are tools for managing cardiovascular and metabolic risk. 

That difference shapes every decision I make about prescribing them. 

I start by looking at risk, not weight. 

When I consider whether a patient should take a GLP-1 agonist, my first question isn’t, “How much weight do they need to lose?” 

Instead, I ask, “What is driving this patient’s long-term risk?” 

If a patient has atherosclerotic cardiovascular disease, like a previous heart attack, stroke, or known plaque, the conversation is very different than with someone who is healthy but worried about weight. 

 

When you add metabolic factors like insulin resistance, high triglycerides, central obesity, and early glucose problems, a pattern starts to emerge. 

 

It’s not just about the number on the weighing scale. It’s about the biological factors that may raise the risk of future health problems. In this context, GLP-1 receptor agonists become important. 

Preventive cardiology changes the lens 

At Pulse Perfect, our approach is based on preventive cardiology, but not just in the traditional sense of “catching things early.” 

 

We focus on precision. We view cardiovascular risk as a combination of several factors: lipid particle burden, plaque volume and composition, inflammation, metabolic health, fitness capacity, and body composition. 

 

Each of these factors tells part of the story and needs its own intervention. 

In this model, we don’t prescribe GLP-1 receptor agonists on their own. We prescribe them only when they match a specific risk we’ve identified. 

That’s what sets our approach apart. 

When I Prescribe 

In my practice, the best reason to use these medications is for patients who have both established cardiovascular disease and metabolic problems. 

These patients already have cardiovascular disease, and several factors are making it worse. 

For this group, I’m not aiming for small changes. I want treatments that can change the course of their health. 

GLP-1 receptor agonists are a good option here because they affect several systems at once, including glucose control, inflammation, appetite, visceral fat, and blood vessel health. 

But I never decide to use them based only on weight. The choice depends on whether they address a specific problem we’ve found. 

What I don’t use them for 

It’s just as important to discuss when I choose not to prescribe them. 

If someone wants a shortcut that replaces healthy habits, discipline, or the effort needed to improve metabolic health, this is not the right solution. 

It’s not that the drug won’t work, but it would be used for the wrong reason. 

In the Pulse Perfect approach, every treatment must answer one question:What risk are we targeting? 

If we can’t answer that question clearly, I don’t prescribe the drug. I’m also careful with patients whose main goal is appearance rather than health. 

These drugs are too important to be used just for looks. 

This is never a decision made in isolation 

A common misconception about GLP-1 drugs is that they can replace other treatments. 

 

They don’t. GLP-1 drugs don’t replace statins for people with heart disease. They don’t take the place of blood pressure control, regular exercise, better fitness, or ApoB reduction. They work alongside these treatments. 

 

At Pulse Perfect, we use a layered approach to treatment. Statins, PCSK9 inhibitors, GLP-1 agonists, structured exercise, and metabolic optimization all play a part. 

The question isn’t, “Which one should we pick?” It’s, “Which combination does this patient need, and why?” 

What I tell my patients 

This is often the part that changes everything. When I prescribe a GLP-1 agonist, I don’t present it as a weight loss solution. 

I tell them, “This will likely help you lose weight. That’s real. But that’s not the primary reason I’m prescribing it.” 

Then I explain: “You have an underlying cardiovascular risk. And this medication has been shown to reduce the likelihood of heart attack and cardiovascular death in patients like you.” 

That shift in perspective matters because it helps patients see the medication as essential, not just optional. 

I also tell them what it does not do. It does not replace a statin. 
It does not replace improving your VO₂ max. It does not replace achieving optimal ApoB levels. 

It’s just one part of a precise treatment plan, and its value depends on how it fits into the whole system. 

It’s not a Shortcut 

The popularity of GLP-1 drugs has led to a risky idea: that they are an easy way to lose weight. In reality, they are not a shortcut. 

They can boost results, but they work best when added to a structured health plan. Without that, they may cause some change, but not a real transformation. 

And in cardiovascular care, transformation is what matters. 

When I choose not to prescribe 

Sometimes, the answer is no, or not yet. 

If the patient’s risk doesn’t justify it, if we haven’t fully evaluated the causes, or if expectations are off, I hold off on prescribing. 

In these situations, the drug might show visible results but not lead to meaningful outcomes, which isn’t the goal. 

The goal is precision. 

The takeaway 

If you think this is just about adding another medication, you’re missing the point. It’s really about understanding risk in depth and treating it wisely. 

Sometimes, GLP-1 receptor agonists are part of that answer. Sometimes, they’re not. 

What matters is that when these drugs are used, it’s a careful and intentional choice. It’s not just about adding another drug, but about treating the right risk, in the right patient, for the right reason.